Document Detail

Hyper-expression of PAX2 in human metastatic prostate tumors and its role as a cancer promoter in an in vitro invasion model.
MedLine Citation:
PMID:  23765687     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Metastasis is a consequence of many biological events, during which cancer stem cells are shifted into a malignant state. Among these events, invasion of prostate cancer cells into host tissues is possible to be assessed by means of an in vitro invasion model, and is thought to be coupled to altered expression of membrane proteins. Dysregulated functions of the factors regulating organogenesis during embryogenesis are known to facilitate metastasis of many types of cancers. PAX2 (paired box 2) is a member of the PAX transcription factor family, which regulates prostatic ductal growth and branching in organogenesis of mammalian prostates. However, the role of PAX2 in prostate cancer development remains to be determined.
METHODS: PAX2 expression in human prostate cancers and normal prostate epithelium were examined by quantitative RT-PCR and immunohistochemistry. Matrigel invasion assay and a gene array analysis were performed using prostate cancer cell lines transfected with either control or PAX2 siRNA.
RESULTS: In human prostate cancers, PAX2 was hyper-expressed in metastatic cancers, but was expressed at lower levels in non-metastatic cancers. Consistent with this, PAX2 knockdown repressed cell growth and invasion in a Matrigel invasion assay. Gene ontology analysis revealed that many cell membrane proteins were downregulated after PAX2 knockdown.
CONCLUSIONS: Our data suggested that PAX2 hyper-expression promotes the development of the metastatic state in prostate cancer cells, presumably through upregulating the expression of cell membrane proteins.
Takashi Ueda; Saya Ito; Takumi Shiraishi; Prakash Kulkarni; Akihisa Ueno; Hideo Nakagawa; Yasunori Kimura; Fumiya Hongo; Kazumi Kamoi; Akihiro Kawauchi; Tsuneharu Miki
Related Documents :
23778527 - Hypoxia regulates fgfr3 expression via hif-1α and mir-100 and contributes to cell surv...
25046127 - Immobilizing gold nanoparticles in mesoporous silica covered reduced graphene oxide: a ...
24470767 - Management of cancer pain: 1. wider implications of orthodox analgesics.
23349697 - Cc-chemokine ligand 18 induces epithelial to mesenchymal transition in lung cancer a549...
19775337 - Biologic markers in endometrial cancer treatment.
12849627 - 'i don't have any energy': the experience of fatigue in young adult survivors of childh...
Publication Detail:
Type:  Journal Article     Date:  2013-06-14
Journal Detail:
Title:  The Prostate     Volume:  73     ISSN:  1097-0045     ISO Abbreviation:  Prostate     Publication Date:  2013 Sep 
Date Detail:
Created Date:  2013-08-15     Completed Date:  2013-10-30     Revised Date:  2014-03-04    
Medline Journal Info:
Nlm Unique ID:  8101368     Medline TA:  Prostate     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1403-12     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Wiley Periodicals, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Line, Tumor
Cell Proliferation
Gene Expression Regulation, Neoplastic
Neoplasm Metastasis / genetics*,  pathology
PAX2 Transcription Factor / genetics*,  metabolism
Prostate / metabolism*,  pathology
Prostatic Neoplasms / genetics*,  metabolism,  pathology
Reg. No./Substance:
0/PAX2 Transcription Factor; 0/PAX2 protein, human
Erratum In:
Prostate. 2014 Apr;74(4):450

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis.
Next Document:  3D structural patterns in scalable, elastomeric scaffolds guide engineered tissue architecture.